Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting severe unmet medical needs including cancer, autoimmune disorders, and infectious disease.
AAT has a number of therapeutic antibodies under development. These drug candidates were derived from AAT's proprietary discovery technologies that include "CoALT" human and immune repertoire libraries, proprietary library screening technologies, an antibody-mediated cancer vaccine platform, and rational design of therapeutic antibodies.
Last Updated: 07-28-2006